Advertisement

Topics

Adrenergic modifiers - Biotech, Pharma and Life Science Channel

16:37 EDT 28th June 2016 | BioPortfolio

PubMed Articles [328 Associated PubMed Articles listed on BioPortfolio]

Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.

This article reviews current pharmacologic treatment options for 3 common men's health concerns: hypogonadism, erectile dysfunction (ED), and benign prostatic hyperplasia (BPH). Specific topics addres...

A comparison of control banding tools for nanomaterials.

Control banding (CB) is a useful approach to evaluate and control the risk of exposure to nanomaterials (NM) due to uncertainty surrounding their toxicity and challenges associated with their measurem...

Identification of human sympathetic neurovascular control using multivariate wavelet decomposition analysis.

The dynamic regulation of cerebral blood flow (CBF) is thought to involve myogenic and chemoreflex mechanisms but the extent to which the sympathetic nervous system also plays a role remains debated. ...

Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation.

Myocardial ischemia carries dual risk for initiating atrial and ventricular arrhythmias that can be exacerbated by adrenergic stimulation.

Review of the Ecotoxicological Properties of the Methylenedianiline Substances.

Concerning chronic toxicity, D. magna is the most sensitive species tested against MDA aquatic exposures, with a 21 days-NOEC of 0.00525 mg/L. Exposure of daphnids takes place via the aquatic phase....

Subtype-specific patterns of molecular mutations in acute myeloid leukemia.

Acute myeloid leukemia (AML) can be grouped into morphologically or genetically defined subtypes. Today, the AML phenotype-genotype associations, ie, FAB/WHO definitions and recurrent molecular mutati...

Intergenic GWAS SNPs are Key Components of the Spatial and Regulatory Network for Human Growth.

Meta-analysis of genome-wide association studies (GWAS) has resulted in the identification of hundreds of genetic variants associated with growth and stature. Determining how these genetic variants in...

Renal denervation improves cardiac function in rats with heart failure: effects on expression of β-adrenoceptors.

Chronic activation of the sympathetic drive contributes to cardiac remodeling and dysfunction during chronic heart failure (CHF). The present study was undertaken to assess if renal denervation (RDN) ...

Carvedilol-responsive microRNAs, miR-199a-3p and -214 protect cardiomyocytes from simulated ischemia-reperfusion injury.

The nonselective β-adrenergic receptor antagonist (β-blocker) carvedilol has been shown to protect against myocardial injury, but the detailed underlying mechanisms are unclear. We recently reported...

Doxazosin, an α-1-adrenergic-receptor Antagonist, for Nightmares in Patients with Posttraumatic Stress Disorder and/or Borderline Personality Disorder: a Chart Review.

Objective: Centrally active α-1-adrenergic-receptor antagonists such as prazosin are effective in the treatment of nightmares in patients with posttraumatic stress disorder (PTSD). A pharmacological ...

News Articles [54 Associated News Articles listed on BioPortfolio]

Pepducins Bias Cardiac Cell Receptor Signaling, Favor Stronger Beating

Experiments with pepducins, peptides derived from receptor molecules, may lead to a new class of drugs for heart disease. Certain pepducins, report scientists based at Thomas Jefferson University, a...

Central-acting agents

Central-acting agents, also called central adrenergic inhibitors, treat conditions such as high blood pressure and drug or alcohol withdrawal by affecting your nervous system.

Researchers discover a new way to keep the heart pumping, which could lead to new drugs for heart disease

About 5.7 million Americans have heart failure, half of whom will die from the disease within 5 years, according to the Centers for Disease Control and Prevention (CDC). Two processes help drive the d...

Hypertrophic Cardiomyopathy Therapeutics Market to Reach USD 1.2 Billion by 2020

Maryland Heights, MO, June 26, 2016 --(PR.com)-- According to a market research report published by iHealthcareAnalyst, Inc., Hypertrophic Cardiomyopathy Therapeutics Market – Global HCM Drug C...

Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers

FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers  TORONTO, June 23, 2016 /PRNewswire/ - FACIT has announced the creation of a new Ontario biotechnolog...

Parental epigenetic asymmetry of PRC2-mediated histone modifications in the Arabidopsis endosperm

Parental genomes in the endosperm are marked by differential DNA methylation and are therefore epigenetically distinct. This epigenetic asymmetry is established in the gametes and maintained after fer...

Phosphorylation of Cav1.2 on S1928 uncouples the L-type Ca2+ channel from the {beta}2 adrenergic receptor

Agonist-triggered downregulation of β-adrenergic receptors (ARs) constitutes vital negative feedback to prevent cellular overexcitation. Here, we report a novel downregulation of β2AR signal...

Alpha blockers

Alpha blockers, also called alpha-adrenergic antagonists, treat several conditions, such as high blood pressure and enlarged prostate. Find out more about these medications.

Basic research: Role of the β3 adrenergic receptor in renal function

Galderma announces Mirvaso gel pump dispenser for treating rosacea

Galderma Laboratories recently announced that a new pump dispenser design for Mirvaso topical gel, 0.33% is available to treat persistent erythema associated with rosacea in adults.Mirvaso (brimonidin...

Events [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Partikula LLC

Partikula is a preclinical stage biotechnology company focused on developing novel therapies for cancer and other diseases based on platform chemistry technologies, including its ...

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Innate Therapeutics Limited

Innate Therapeutics Limited is a public unlisted biopharmaceutical company based in Auckland. The company is focused on the development of a new generation of immune response modi...

Clinical Trials [122 Associated Clinical Trials listed on BioPortfolio]

Pharmacological Activation of Brown Adipose Tissue Metabolism

Lean tissue intracellular triglycerides (ICTG) accretion is an important marker of lean tissue lipotoxicity that significantly contributes to the development of type 2 diabetes (T2D). The ...

Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study

The purpose of this study is: (1) to examine the effectiveness of reconsolidation blockade as a treatment for trauma-related disorders, (2) to evaluate the feasibility of implementing this...

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis

Bladder pain syndrome/interstitial cystitis (BPS/IC) is a difficult disease to both diagnose and treat. It is defined as an unpleasant sensation (pain, pressure, or discomfort) perceived t...

The Effects of Dexmedetomidine on Intestine and Other Organ Damages After Cardiac Surgeries

Cardiac surgery with cardiopulmonary bypass (CPB) provokes a systemic inflammatory response that can often lead to dysfunction of major organs. Activation of the contact system, endotoxemi...

Use of Preanesthetic Dexmedetomidine in Elderly, Treated-hypertensive Patients

Background: Dexmedetomidine is an alpha 2 adrenergic agonist with sedative, anxiolytic, and analgesic properties. This study was designed to evaluate the inhibitory effects of preoperative...

Rasch-analysis of Clinical Severity in FSHD

The purpose of this study is to make a standardized and scalable Rasch-built clinical severity scale to help in finding genetic and environmental modifiers of disease in Facioscapulohumera...

Cardiac Output Changes in Cesarean Section

Since 2011, phenylephrine was recommended as the preferred drug to maintain blood pressure in obstetric anesthesia.Phenylephrine, an α adrenoceptor agonist, can induce peripheral vasocons...

Norepinephrine Exerts an Inotropic Effect at the Early Phase of Human Septic Shock

Norepinephrine (NE) is a potent vasopressor used in septic shock to reverse hypotension. Early infusion of NE was associated with a favorable clinical outcome in a large cohort of patients...

Pilot - Peri-operative Beta Blockade

Perioperative cardiac adverse events [heart injuries caused by general anesthesia and surgical procedures] are a significant public health issue, with more than 60,000 deaths per annum in ...

Unravelling Effectiveness of a Nurse-led Behavior Change Intervention to Enhance Physical Activity in Patients

A two-armed, cluster randomized controlled trial will be conducted comparing the Activate intervention with care as usual in 26 general practices in the Netherlands, in which approximately...

Videos

None available.

Medical and Biotech [MESH] Definitions

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.

A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). beta-3 Adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown ADIPOCYTES and are involved in modulating ENERGY METABOLISM and THERMOGENESIS.

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Quick Search
Advertisement
 
review and buy Adrenergic modifiers market research data and corporate reports here

Channels Quicklinks